CTOs on the Move

Preferred Health Professionals

www.phpkc.com

 
Preferred Health Professionals is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.phpkc.com
  • 9393 W 110th St Ste 200
    Overland Park, KS USA 66210
  • Phone: 816.823.6700

Executives

Name Title Contact Details

Similar Companies

InterGanics

InterGanics is a global solution-driven company that supports ingredients and finish products manufacturers to design an environmentally safe, socially responsible and economically sustainable sourcing strategy around Organic, Non-GMO and Specialty products.

De Kroyft-Metz

De Kroyft-Metz is a Peoria, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Adena Health System

Adena Health System offers a variety of Behavioral Health Services. Our mission is to assist each person in achieving the highest quality of life possible.

Western Berks Ambulance Association

Western Berks Ambulance Association is a Reading, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Synthetic Biologics

Synthetic Biologics, Inc. trades on the NYSE MKT, LLC under the symbol "SYN". The Company`s principal executive offices are located in Rockville, MD, and the finance and administrative office is located in Ann Arbor, MI. Synthetic Biologics, Inc. is a microbiome-focused, clinical-stage company developing therapeutics to protect the microbiome while targeting pathogen-specific diseases. The Company`s lead candidates in Phase 2 development include SYN-004 which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection and antibiotic-associated diarrhea (AAD), and SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat the underlying cause of irritable bowel syndrome with constipation (IBS-C). In addition, the Company is developing a monoclonal antibody combination for the treatment of Pertussis, and a Phase 2 oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS.